Match!
Emilie Mamessier
Aix-Marseille University
ImmunologyCancer researchBreast cancerMedicineBiology
46Publications
20H-index
1,641Citations
What is this?
Publications 49
Newest
#1Anaïs AulasH-Index: 2
#2Pascal FinettiH-Index: 43
Last. Emilie MamessierH-Index: 20
view all 7 authors...
#1T. Delayre (AMU: Aix-Marseille University)
#2Théophile Guilbaud (AMU: Aix-Marseille University)H-Index: 3
Last. David Jérémie Birnbaum (AMU: Aix-Marseille University)H-Index: 5
view all 10 authors...
BACKGROUND: The prognosis of patients with pancreatic cancer remains poor and novel therapeutic targets are required urgently. Treatment resistance could be due to the tumour microenvironment, a desmoplastic stroma consisting of cancer-associated fibroblasts and tumour-infiltrating lymphocytes (TILs). The aim of the study was to evaluate the prognostic value of TILs and cancer-associated fibroblasts (CAFs) in pancreatic cancer of the body and tail. METHODS: Using tissue microarray from resected ...
Source
#1Anaïs AulasH-Index: 2
#2Pascal FinettiH-Index: 43
Last. Emilie MamessierH-Index: 20
view all 7 authors...
#2Pascal Finetti (AMU: Aix-Marseille University)H-Index: 43
Last. François Bertucci (AMU: Aix-Marseille University)H-Index: 32
view all 7 authors...
ABSTRACTAdrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy are urgently needed. Targeting the...
Source
#2Pascal FinettiH-Index: 43
Last. François BertucciH-Index: 52
view all 9 authors...
Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with di...
Source
#1Alexia LoprestiH-Index: 3
#2Fabrice MalergueH-Index: 1
Last. Emilie MamessierH-Index: 20
view all 12 authors...
1 CitationsSource
#1Yuchen Guo (University of Montpellier)
#2Monica Gabola (University of Montpellier)
Last. Michael Hahne (University of Montpellier)H-Index: 42
view all 21 authors...
To clarify the function of cyclin A2 in colon homeostasis and colorectal cancer (CRC) we generated mice deficient for cyclin A2 in colonic epithelial cells (CEC). Colons of those mice displayed architectural changes in the mucosa, and signs of inflammation as well as an increased proliferation of CEC associated with the appearance of low- and high-grade dysplasia. The main initial events triggering those alterations in cyclin A2 deficient CEC appear to be abnormal mitoses and DNA damage. Cyclin ...
Source
#2Emilie MamessierH-Index: 20
Last. Renaud SabatierH-Index: 10
view all 7 authors...
Ovarian cancers (OvC) are frequent, with more than 22,000 new cases each year for 14,000 deaths in the United States. Except for patients with BRCA1 or BRCA2 mutations, diagnostic methods, prognostic tools, and therapeutic strategies have not much improved in the last two decades. High throughput tumor molecular analyses have identified important alterations involved in ovarian carcinoma growth and spreading. However, these data have not modified the clinical management of most of patients. More...
Source
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed XPO1 m...
1 CitationsSource
#1David J. BirnbaumH-Index: 9
#2François BertucciH-Index: 52
Last. Emilie MamessierH-Index: 20
view all 5 authors...
The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected clinicopathological and gene expression data from 249 resected PDAC samples from public data sets, and we compared data between 208 head and 41 B/T samples. The 2-year overall survival (OS) was better for the head than for the B/T PDACs (44 vs. 27%, p = 0.043), especially when comparing tumors with similar TNM classification (T3/4N0M0: 67% v...
1 CitationsSource
12345